Lithium Use in Pregnancy and the Risk of Cardiac Malformations

BACKGROUND There has been concern that exposure to lithium early in pregnancy may be associated with a marked increase in the risk of Ebstein's anomaly (a right ventricular outflow tract obstruction defect) in infants and overall congenital cardiac defects, but data are conflicting and limited. METHODS We conducted a cohort study involving 1,325,563 pregnancies in women who were enrolled in Medicaid and who delivered a live‐born infant between 2000 and 2010. We examined the risk of cardiac malformations among infants exposed to lithium during the first trimester as compared with unexposed infants and, in secondary analyses, with infants exposed to another commonly used mood stabilizer, lamotrigine. Risk ratios and 95% confidence intervals were estimated with control for psychiatric and medical conditions, medications, and other potential confounders. RESULTS Cardiac malformations were present in 16 of the 663 infants exposed to lithium (2.41%), 15,251 of the 1,322,955 nonexposed infants (1.15%), and 27 of the 1945 infants exposed to lamotrigine (1.39%). The adjusted risk ratio for cardiac malformations among infants exposed to lithium as compared with unexposed infants was 1.65 (95% confidence interval [CI], 1.02 to 2.68). The risk ratio was 1.11 (95% CI, 0.46 to 2.64) for a daily dose of 600 mg or less, 1.60 (95% CI, 0.67 to 3.80) for 601 to 900 mg, and 3.22 (95% CI, 1.47 to 7.02) for more than 900 mg. The prevalence of right ventricular outflow tract obstruction defects was 0.60% among lithium‐exposed infants versus 0.18% among unexposed infants (adjusted risk ratio, 2.66; 95% CI, 1.00 to 7.06). Results were similar when lamotrigine‐exposed infants were used as the reference group. CONCLUSIONS Maternal use of lithium during the first trimester was associated with an increased risk of cardiac malformations, including Ebstein's anomaly; the magnitude of this effect was smaller than had been previously postulated. (Funded by the National Institute of Mental Health.)

[1]  Krista F. Huybrechts,et al.  A Propensity-score-based Fine Stratification Approach for Confounding Adjustment When Exposure Is Infrequent , 2017, Epidemiology.

[2]  K. Dimopoulos,et al.  Antidepressant use in pregnancy and the risk of cardiac defects. , 2014, The New England journal of medicine.

[3]  A. Ornoy,et al.  Pregnancy outcome following in utero exposure to lithium: a prospective, comparative, observational study. , 2014, The American journal of psychiatry.

[4]  Mary K. Kowal,et al.  Validity of maternal and infant outcomes within nationwide Medicaid data , 2014, Pharmacoepidemiology and drug safety.

[5]  W. Callaghan,et al.  Development of a Comorbidity Index for Use in Obstetric Patients , 2013, Obstetrics and gynecology.

[6]  Mary K. Kowal,et al.  Harnessing the Medicaid Analytic eXtract (MAX) to Evaluate Medications in Pregnancy: Design Considerations , 2013, PloS one.

[7]  S. Hernández-Díaz,et al.  Comparative safety of antiepileptic drugs during pregnancy , 2013, Neurology.

[8]  S. Hernández-Díaz,et al.  Algorithms to estimate the beginning of pregnancy in administrative databases , 2013, Pharmacoepidemiology and drug safety.

[9]  L. Brandt,et al.  Risks of adverse pregnancy and birth outcomes in women treated or not treated with mood stabilisers for bipolar disorder: population based cohort study , 2012, BMJ : British Medical Journal.

[10]  L. Gram,et al.  Lamotrigine versus lithium as maintenance treatment in bipolar I disorder: an open, randomized effectiveness study mimicking clinical practice. The 6th trial of the Danish University Antidepressant Group (DUAG-6). , 2010, Bipolar disorders.

[11]  M. Loane,et al.  Valproic acid monotherapy in pregnancy and major congenital malformations. , 2010, The New England journal of medicine.

[12]  P. Austin.  Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples , 2009, Statistics in medicine.

[13]  B. Källén,et al.  Maternal Use of Antipsychotics in Early Pregnancy and Delivery Outcome , 2008, Journal of clinical psychopharmacology.

[14]  A. Ornoy,et al.  Is lithium a real teratogen? What can we conclude from the prospective versus retrospective studies? A review. , 2008, The Israel journal of psychiatry and related sciences.

[15]  R. Baldessarini,et al.  Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation. , 2007, The American journal of psychiatry.

[16]  E. Leibenluft,et al.  Management of bipolar disorder during pregnancy and the postpartum period. , 2004, The American journal of psychiatry.

[17]  F. Zitman,et al.  P.1.169 Bipolar and pregnant? No problem! A clinical evaluation of lithium use during pregnancy , 2003, European Neuropsychopharmacology.

[18]  J. Boughman,et al.  Ebstein's malformation of the tricuspid valve: genetic and environmental factors. The Baltimore-Washington Infant Study Group. , 1994, Teratology.

[19]  J. Jefferson,et al.  A reevaluation of risk of in utero exposure to lithium. , 1994, JAMA.

[20]  Prospective multicentre study of pregnancy outcome after lithium exposure during first trimester , 1992, The Lancet.

[21]  A. Czeizel,et al.  Evaluation of drug intake during pregnancy in the Hungarian Case-Control Surveillance of Congenital Anomalies. , 1990, Teratology.

[22]  L. Edmonds,et al.  Ebsteins anomaly and maternal lithium exposure during pregnancy , 1990 .

[23]  T. Einarson,et al.  A case-control study on the association between first trimester exposure to lithium and Ebstein's anomaly. , 1990, The American journal of cardiology.

[24]  G. Greenberg,et al.  Drugs in Pregnancy and Lactation , 1990 .

[25]  A. Sípek.  Lithium and Ebstein's anomaly. , 1989, Cor et vasa.

[26]  B. Källén.  Comments on teratogen update: lithium , 1988 .

[27]  B. Källén,et al.  Lithium and Pregnancy. A Cohort Study on Manic-Depressive Women , 1984 .

[28]  P. W. Willis,et al.  Maternal Lithium and Neonatal Ebstein's Anomaly: Evaluation with Cross-Sectional Echocardiography , 1984, American journal of perinatology.

[29]  P. K. Dixit,et al.  Teratogenic effects of lithium in mice. , 1982, Teratology.

[30]  M. Tynan,et al.  PRENATAL ECHOCARDIOGRAPHIC SCREENING FOR EBSTEIN'S ANOMALY FOR MOTHERS ON LITHIUM THERAPY , 1982, The Lancet.

[31]  J. Marín-García,et al.  Tricuspid valve regurgitation and lithium carbonate toxicity in a newborn infant. , 1981, American journal of diseases of children.

[32]  E. O. Ledbetter,et al.  Ebstein's anomaly of the tricuspid valve associated with prenatal exposure to lithium carbonate. , 1980, American journal of diseases of children.

[33]  M. Weinstein.  Lithium Treatment of Women During Pregnancy and in the Post-Delivery Period , 1980 .

[34]  A. Rane,et al.  Effects of maternal lithium therapy in a newborn infant. , 1978, The Journal of pediatrics.

[35]  M. Weinstein,et al.  Cardiovascular malformations with lithium use during pregnancy. , 1975, The American journal of psychiatry.

[36]  J. Nora,et al.  Letter: Lithium, Ebstein's anomaly, and other congenital heart defects. , 1974, Lancet.

[37]  M. Schou,et al.  Lithium and pregnancy. I. Report from the Register of Lithium Babies. , 1973, British medical journal.

[38]  M. Schou,et al.  Lithium and Pregnancy—I, Report from the Register of Lithium Babies , 1973 .

[39]  K. Szabo.  Teratogenic Effect of Lithium Carbonate in the Foetal Mouse , 1970, Nature.